Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKAE cells in relapsed multiple myeloma
NCT02481934Phase 1Completed
- Start
- Mar 2013
- Primary completion
- Jul 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of expanded and activated autologous natural killer cells in multiple myeloma (MM). Primary endpoint: Adverse Events at 16 months. Started Mar 2013; status: completed.
02
Drugs
expanded and activated autologous natural killer cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02481934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481934.